Close Menu

NEW YORK(GenomeWeb) – Biodesix said this week that it has entered a partnership with UK-based genomics firm Inivata to develop and commercialize a next-generation sequencing-based blood test for clinical use in lung cancer.

The two companies are still in the early days of determining what intended uses to pursue under the collaboration, Biodesix CEO David Brunel told GenomeWeb. He cited as likely potential directions development of tests for guiding therapy in late-stage patients who have exhausted conventional treatment plans and support of drug development efforts.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new paper says an effort to introduce gene drives into mosquitos altered the genetic makeup of the local mosquitos, but the company behind the project says the paper is flawed.

Researchers examine changes in the genomes of emmer wheat populations where the climate has warmed, the BBC reports.

Virginia's Department of Forensic Science is offering attorneys a course on DNA testing, the Virginian-Pilot reports.

In Cell this week: microinjection of CRISPR-Cas9 enables targeted mutations in Anolis, melanoma proteomic profiling, and more.

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.